483 related articles for article (PubMed ID: 23587496)
1. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
[TBL] [Abstract][Full Text] [Related]
3. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
6. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
7. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
[TBL] [Abstract][Full Text] [Related]
8. Low Indeterminate Rates Associated With Use of the QuantiFERON-TB Gold In-Tube Test in Children With Inflammatory Bowel Disease on Long-term Infliximab.
Vortia E; Uko VE; Yen-Lieberman B; Frawley J; Worley SE; Danziger-Isakov L; Kaplan B; Mahajan L
Inflamm Bowel Dis; 2018 Mar; 24(4):877-882. PubMed ID: 29562270
[TBL] [Abstract][Full Text] [Related]
9. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
11. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers.
Saraceno R; Specchio F; Chiricozzi A; Sarmati L; Amicosante M; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2014 Feb; 14(2):151-6. PubMed ID: 24303977
[TBL] [Abstract][Full Text] [Related]
13. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.
Helwig U; Müller M; Hedderich J; Schreiber S
J Crohns Colitis; 2012 May; 6(4):419-24. PubMed ID: 22398067
[TBL] [Abstract][Full Text] [Related]
15. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
[TBL] [Abstract][Full Text] [Related]
16. Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents.
Klein M; Jarosová K; Forejtová S; Bečvář R; Sedová L; Pavelka K; Simková G; Svobodová R; Hviscová K; Mann H; Půtová I; Vencovský J
Clin Exp Rheumatol; 2013; 31(1):111-7. PubMed ID: 23101473
[TBL] [Abstract][Full Text] [Related]
17. Can ELISpot replace the tuberculin skin test for latent tuberculosis?
Greveson K
Br J Nurs; 2009 Nov 12-25; 18(20):1248-54. PubMed ID: 20081663
[TBL] [Abstract][Full Text] [Related]
18. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
[TBL] [Abstract][Full Text] [Related]
20. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]